Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effectiveness of etanercept vs cyclophosphamide as treatment for patients with amyloid A amyloidosis secondary to rheumatoid arthritis.

Rheumatology (Oxford, England) - 1 Nov 2012

Nakamura Tadashi, Higashi Syu-Ichi, Tomoda Kunihiko, Tsukano Michishi, Shono Masahiro

Abstract excerpt

OBJECTIVES: To compare the effectiveness of an alkylating agent with that of a biologic agent in the treatment of patients with amyloid A (AA) amyloidosis secondary to RA and to assess the association of the serum AA (SAA) 1.3 allele with treatment. METHODS: CYC and etanercept (ETN) were administered to 62 and 24 RA patients, respectively, who were confirmed with biopsy as having AA amyloidosis. We evaluated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloidosis
Share to Cause of Death

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclophosphamide

Share to Etanercept

Share to Glomerular Filtration Rate

Share to Kidney Diseases

Share to Receptors, Tumor Necrosis Factor

Share to Serum Amyloid A Protein

Source

Identifiers

PMID: 22879465
DOI: 10.1093/rheumatology/kes190

Genes

SAA1
CRP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effectiveness of etanercept vs cyclophosphamide as treatment for patients with amyloid A amyloidosis secondary to rheumatoid arthritis.PMID 22879465Read ↗

Etanercept can induce resolution of renal deterioration in patients with amyloid A amyloidosis secondary to rheumatoid arthritis.Semantic proximity Read ↗

Clinical strategies for amyloid A amyloidosis secondary to rheumatoid arthritis.Semantic proximity Read ↗

Efficacy of cyclophosphamide combined with prednisolone in patients with AA amyloidosis secondary to rheumatoid arthritis.Semantic proximity Read ↗

Significance of SAA1.3 allele genotype in Japanese patients with amyloidosis secondary to rheumatoid arthritis.Semantic proximity Read ↗

SAA1 gene polymorphisms and the risk of AA amyloidosis in Japanese patients with rheumatoid arthritis.Semantic proximity Read ↗

Ageing: a risk factor for amyloid A amyloidosis in rheumatoid arthritis.Semantic proximity Read ↗

A novel single-nucleotide polymorphism at the 5'-flanking region of SAA1 associated with risk of type AA amyloidosis secondary to rheumatoid arthritis.Semantic proximity Read ↗

SAA1 alleles as risk factors in reactive systemic AA amyloidosis.Semantic proximity Read ↗

Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome.Semantic proximity Read ↗

Relative serum amyloid A (SAA) values: the influence of SAA1 genotypes and corticosteroid treatment in Japanese patients with rheumatoid arthritis.Semantic proximity Read ↗

An allele of serum amyloid A1 associated with amyloidosis in both Japanese and Caucasians.Semantic proximity Read ↗

Measurement of serum amyloid A1 (SAA1), a major isotype of acute phase SAA.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.